FXR/TGR5双重激动剂可预防糖尿病和肥胖相关肾病进展
该研究在链脲佐菌素诱导的DBA/2J糖尿病小鼠、db/db 2型糖尿病小鼠及高脂饮食诱导肥胖的C57BL/6J小鼠中给予FXR/TGR5双重激动剂INT-767,并比较选择性FXR激动剂OCA与TGR5激动剂INT-777的单独效应。结果显示INT-767改善蛋白尿并预防足细胞损伤、系膜扩张和肾小管间质纤维化,且OCA与INT-777调控不同肾脏信号通路,提示FXR与TGR5信号可能为糖尿病和肥胖相关肾病的治疗靶点。
要点
- INT-767在糖尿病小鼠中改善蛋白尿并预防足细胞损伤、系膜扩张和肾小管间质纤维化。
- 选择性FXR激动剂OCA与TGR5激动剂INT-777调控不同的肾脏信号通路。
- INT-767协调激活AMPK-SIRT1-PGC-1α等通路并抑制内质网应激及增强的肾脏脂肪酸和胆固醇代谢。
核心结论
- FXR/TGR5双重激动剂INT-767可改善糖尿病小鼠蛋白尿并预防肾脏结构损伤。
- FXR与TGR5通过不同或协同信号通路发挥肾脏保护作用,可能成为糖尿病和肥胖相关肾病的治疗靶点。
研究设计与样本
- 在链脲佐菌素诱导的DBA/2J糖尿病小鼠、db/db 2型糖尿病小鼠及高脂饮食诱导肥胖的C57BL/6J小鼠中给予FXR/TGR5双重激动剂INT-767。
- 在糖尿病小鼠中另比较选择性FXR激动剂OCA与TGR5激动剂INT-777的单独效应。
主要发现
- INT-767改善糖尿病DBA/2J和db/db小鼠的蛋白尿,并预防足细胞损伤、系膜扩张和肾小管间质纤维化。
- INT-767协调激活AMPK、SIRT1、PGC-1α、SIRT3、ERRα和Nrf-1信号 cascade,抑制内质网应激,并抑制增强的肾脏脂肪酸和胆固醇代谢。
- 在高脂饮食诱导肥胖小鼠中,INT-767预防线粒体功能障碍和氧化应激(NADH荧光寿命成像判定)及肾脏纤维化(二次谐波成像显微镜判定)。
- OCA与INT-777调控参与糖尿病肾病发病和治疗的 distinct 肾脏信号通路。
临床怎么用
- FXR/TGR5双重激动可能作为糖尿病和肥胖相关肾病的潜在治疗策略。
- INT-767在动物模型中改善蛋白尿并减轻肾脏病理损伤,支持进一步临床转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bile acids are ligands for the nuclear hormone receptor farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5. We have shown that FXR and TGR5 have renoprotective roles in diabetes- and obesity-related kidney disease. Here, we determined whether these effects are mediated through differential or synergistic signaling pathways. We administered the FXR/TGR5 dual agonist INT-767 to DBA/2J mice with streptozotocin-induced diabetes, db/db mice with type 2 diabetes, and C57BL/6J mice with high-fat diet-induced obesity. We also examined the individual effects of the selective FXR agonist obeticholic acid (OCA) and the TGR5 agonist INT-777 in diabetic mice. The FXR agonist OCA and the TGR5 agonist INT-777 modulated distinct renal signaling pathways involved in the pathogenesis and treatment of diabetic nephropathy. Treatment of diabetic DBA/2J and db/db mice with the dual FXR/TGR5 agonist INT-767 improved proteinuria and prevented podocyte injury, mesangial expansion, and tubulointerstitial fibrosis. INT-767 exerted coordinated effects on multiple pathways, including stimulation of a signaling cascade involving AMP-activated protein kinase, sirtuin 1, PGC-1α, sirtuin 3, estrogen-related receptor-α, and Nrf-1; inhibition of endoplasmic reticulum stress; and inhibition of enhanced renal fatty acid and cholesterol metabolism. Additionally, in mice with diet-induced obesity, INT-767 prevented mitochondrial dysfunction and oxidative stress determined by fluorescence lifetime imaging of NADH and kidney fibrosis determined by second harmonic imaging microscopy. These results identify the renal signaling pathways regulated by FXR and TGR5, which may be promising targets for the treatment of nephropathy in diabetes and obesity.
引用
- Wang XX, Wang D, Luo Y, et al. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. J Am Soc Nephrol. 2017. PMID: 29089371. doi:10.1681/ASN.2017020222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。